DB-1323 / DualityBio, FatiAbGen - LARVOL DELTA

DB-1323, a next-generation mesothelin targeting antibody-drug conjugate, demonstrated anti-tumor activity and favorable safety profile in pre-clinical models (AACR 2026) - "Anti-tumor activity was tested in MSLN-positive pancreatic and ovarian cancer xenograft models compared to that of anetumab ravtansine and other MSLN ADCs. DB-1323 overcomes historical MSLN-targeting liabilities through unique rapid-on/off binding, efficient internalization, and potent topoisomerase I inhibition, delivering superior tumor eradication versus at well-tolerated doses. These data support clinical evaluation of DB-1323 for patients with MSLN expressing tumors."

ADC • Preclinical • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • MSLN